Picture a recipe that nobody has ever actually cooked. No one measured the salt, no one timed the oven, no one tasted the result and adjusted. It just got copied from person to person, each time sounding a little more precise, a little more official, until it read like something out of a trusted cookbook. That is exactly what has happened with IGF-1 LR3 dosing. The microgram numbers you find online, the split schedules, the “run it for six weeks then take a break” advice, all of it looks like a recipe. None of it was ever tested in a kitchen with real people in it.
I want to walk you through this the way I’d explain it to a friend who called me up confused and a little worried. What is this compound, why does nobody have a real dose for it, what should actually worry you, and if you’ve already made up your mind to use it, how do you make that choice less dangerous. As of June 2026, IGF-1 LR3 has no FDA approval, has never gone through human safety review, and is banned in tested sport. The human evidence for it is thin enough that you could read all of it in an afternoon.
What IGF-1 LR3 actually is
Start with the name. IGF-1 stands for insulin-like growth factor 1, a hormone your body makes naturally that helps cells grow, repair, and build muscle. “LR3” refers to a lab modification, a small tweak to the front of the molecule that keeps your body’s binding proteins from grabbing onto it as quickly. Regular IGF-1 gets mopped up and cleared within minutes. The LR3 version sticks around active in your bloodstream for hours instead. Think of it like the difference between a candle and a road flare, same basic idea, but one burns much longer and much hotter.
Here’s the part that matters most, though: this molecule was never built to be a medicine. It was built as a laboratory tool, something scientists add to a dish of cells to make them grow faster, useful at industrial scale in biotech work. Independent antidoping researchers describe it bluntly: it “was never approved for use in humans,” yet it shows up “as black market products for bodybuilding” [C1]. A tool designed to make cells multiply in a flask was never put through the process that would tell us what happens when you put it in a person, at what amount, or for how long.
How the forum “doses” actually got invented
If nobody ran the real trials, where did all those confident numbers come from? Three places, and none of them is a lab.
First, plain old bodybuilding folklore, a number gets repeated enough times across enough forums that repetition starts to feel like proof. Second, some well-meaning person took a result from a mouse study or a petri dish and did rough math to scale it up to a 180-pound human, using guesswork dressed up as arithmetic. Third, the people selling the stuff sometimes suggest an amount, and you should notice that conflict of interest immediately. They are not doctors. They profit when you use more, not less.
None of these three sources is a test kitchen. They’re more like a group chat trading a recipe nobody has cooked, where each retelling adds a confident detail that was never actually measured. When a number gets presented with total certainty, and there’s no clinical trial behind it, treat that certainty itself as the warning sign.
What the actual research shows, and where it stops
I don’t want to leave you with just “nobody knows,” because there is real science underneath this, and it deserves a fair hearing, stated exactly as far as it goes and no further.
In 2004, researchers published a study in the Journal of Cellular Physiology where they applied Long-R3-IGF-I to L6 muscle cells growing in a dish, and the cells multiplied and matured [C3]. That’s a genuine finding with the actual compound, and it shows the molecule does what it was engineered to do: make muscle-lineage cells grow, in a flask, under lab conditions.
Separately, a 2019 study in Muscle & Nerve raised natural IGF-1 levels in mouse muscle using genetic and viral delivery methods, and the mice built real, measurable muscle, with a bigger effect in males than females [C6]. That’s a real animal result, but it used the body’s native IGF-1, not the LR3 analog, and it happened in mice, not people.
Put those two together and you get exactly one honest conclusion: IGF-1 signaling is a plausible way to build muscle. That’s the ceiling. It is not a floor for anything else. It doesn’t tell you a safe dose, a safe schedule, or what happens when this specific lab-derived molecule enters a human bloodstream. A flask is not a person, and a mouse is not a person, and anyone pointing to these two studies as justification for a dosing chart is asking them to hold weight they were never built to carry.
What to actually watch for
This is the part I’d want a friend to sit with, because it’s not scare talk, it’s just what the evidence in hand actually says.
The cancer-risk signal nobody advertises. IGF-1 is a growth signal, and growth signals don’t discriminate between the muscle you want bigger and cells you’d rather not encourage. A 2026 systematic review and meta-analysis in Frontiers in Oncology pooled 16 studies and found that higher blood levels of IGF-1 were associated with increased prostate-cancer risk, with an odds ratio of 1.10 (95% CI, 1.02 to 1.18) [C7]. To be fair to the data, this is an association from observational studies of natural IGF-1, not proof that injecting the LR3 analog causes cancer, and the study authors say the dose-response relationship still isn’t clear. But it’s a real enough signal that deliberately keeping your IGF-1 activity elevated for weeks or months isn’t a neutral choice. More and longer isn’t automatically safer, and here it might be the opposite.
The mystery-ingredient problem. Even if a dose existed, it would only mean something if you actually knew what was in the vial. When independent chemists have tested black-market IGF-1 LR3, the results read like a food-safety report nobody wants. A 2010 case report in Growth Hormone & IGF Research examined one gray-market vial and identified it as His-tagged Long-R3-IGF-I, a form “usually produced for biochemical studies,” concluding it “may rather be a by-product from biochemical studies than synthesized for injection purposes” [C2]. A 2010 review from the Cologne antidoping lab listed “unpurified long-R(3)-IGF-1” among confiscated products [C8]. And a 2021 French antidoping paper found “abundant signs of lower quality, oxidized peptide forms” circulating on the black market [C1]. You can’t measure a careful microgram dose of something you can’t verify. It’s like following a recipe precisely while having no idea if the bag on your counter actually contains flour.
The blood sugar swing. IGF-1’s insulin-like activity is right there in its name, and it’s a real, documented property of the whole IGF-1 family, not internet chatter. Anything that meaningfully cranks up IGF-1 signaling can pull your blood sugar down, sometimes fast, sometimes around workouts when you least expect it. That alone is reason enough not to self-administer this based on a number copied from a screenshot.
Two rules that override the whole dosing conversation
Before we even get to “how much,” two facts sit above the entire question.
If you compete in any tested sport, this decision is already made for you. IGF-1 and its analogs, LR3 included, sit on the World Anti-Doping Agency’s Prohibited List under peptide hormones and growth factors, banned at all times [C-WADA]. There’s no dose small enough to dodge that. A prescription doesn’t change it either.
And the legal ground moved under this whole market in 2026. On March 31, 2026, the FDA sent a batch of warning letters to online peptide sellers, with Gram Peptides among the named recipients, treating peptide products labeled “for research use only” but sold for human use as unapproved new drugs [C-FDA]. Those particular letters named GLP-1 compounds like retatrutide and tirzepatide, not IGF-1 LR3 by name, but the principle applies straight across this market: the research-use sticker on the label is not a legal shield once the obvious purpose is a person injecting it.
How to decide, if you’ve already decided
I’m not going to hand you a dose, because there isn’t an honest one to hand you, and a made-up number is worse than admitting none exists. What I can hand you is the thing that actually changes your risk, which is the channel you get this through, not the microgram count.
There are really only two doors here. Door one is the gray market: a vial stamped “research use only,” shipped from a chemical vendor with no clinician anywhere near the transaction, no screening beforehand, nobody checking on you after. This is precisely the supply stream that antidoping labs keep tearing open and finding degraded, or mislabeled, or simply not what it claims to be.
Door two runs through medical supervision. A clinician actually looks at your health history before anything gets prescribed, decides whether it even fits your situation, and the material comes from a licensed 503A compounding pharmacy rather than an unmarked lab. FormBlends is one telehealth operator built around this supervised model, sourcing from licensed compounding pharmacies and laying the evidence out plainly instead of dressing it up with marketing. Their tracker app, for what it’s worth, is just a logbook for watching how your body responds over time, not a prescription pad and not a checkout cart.
Supervision costs more. You’re looking at roughly $200 to $400 a month through a supervised route versus $60 to $120 for an unsupervised research vial. That gap is basically the whole argument in dollar form: what you’re buying with the extra money is a clinician screening for the real risks above, a licensed pharmacy accountable for what’s actually in the bottle, and a person keeping an eye on how things are going. None of that makes IGF-1 LR3 approved, and none of it invents human safety data that doesn’t exist. It just replaces guesswork with oversight.
The bottom line, plain and simple
There is no research-backed human dose for IGF-1 LR3, for the simple reason that the studies that would establish one were never run. Every protocol circulating online is forum tradition and extrapolation, often leaning on cell and mouse studies that only show a plausible mechanism, never a proven human effect or a safe amount. The real risks worth losing sleep over are the cancer-axis signal, the blood sugar swings, and a gray-market supply that keeps testing out as degraded or unidentifiable. If you’re going to use this anyway, the one choice that actually moves the needle is medical supervision, because the honest answer to “what’s the dose” isn’t a number you found online. It’s “whatever a clinician watching you closely decides, and adjusts as they go.”
Questions people actually ask me
Is there a standard dose of IGF-1 LR3 for bodybuilding? Not in any way that means something. No published human trial has ever tested IGF-1 LR3 for muscle growth, so no amount has ever been weighed against its risks in real people. The microgram numbers online are forum tradition and scaled-up guesses from cell and animal work, dressed up to look like data. Precision isn’t the same thing as proof.
Is IGF-1 LR3 FDA approved, or even legal to buy? No. It’s never been approved for human use, it was engineered as a lab tool rather than a medicine [C1], and the “research use only” label doesn’t make injecting it into a person legal. On March 31, 2026, the FDA sent warning letters to online peptide sellers treating research-labeled products marketed for human use as unapproved drugs [C-FDA], which tells you exactly how that label is being read now.
Does it actually build muscle in people? Nobody’s shown that in a controlled human study, and I’d be lying if I said otherwise. What the science does show is narrower: Long-R3-IGF-I made muscle cells multiply in a dish [C3], and boosting natural IGF-1 built muscle in mice [C6]. That’s a plausible mechanism, not proof it works safely in a human body.
What are the biggest risks? Three stand out to me. Chronically pushing up IGF-1 activity touches a growth pathway that observational research links to higher prostate-cancer risk [C7]. Its insulin-like effect can drop your blood sugar. And gray-market vials keep turning out, when scientists actually test them, to be degraded or mislabeled research material of unknown strength [C2], which means any dose math you do is guessing at best.
Why does supervised access cost so much more than a research vial? Because you’re paying for oversight, not the compound itself. An unsupervised vial runs about $60 to $120 with no screening and the quality issues the labs keep documenting. Supervised access, around $200 to $400 a month, pays for a clinician reviewing your history, a licensed pharmacy accountable for what’s actually in the product, and someone tracking how you respond.
Will this show up on a drug test? If you compete in tested sport, yes. IGF-1 and its analogs, LR3 included, are on WADA’s Prohibited List under peptide hormones and growth factors, banned at all times [C-WADA]. Having a prescription doesn’t exempt you, and there’s no dose low enough to make it acceptable in competition.
What exactly is IGF-1 LR3, and how’s it different from your body’s own IGF-1?
IGF-1 LR3 is a synthetic version of insulin-like growth factor 1 that’s been modified to stick around longer in your bloodstream. Your natural IGF-1 gets grabbed by binding proteins and cleared within minutes. The LR3 tweak makes it slip past those binding proteins, so it stays active for hours instead. That longer activity is exactly why it caught bodybuilders’ attention, and exactly why predicting what it does in a real body is harder.
What does it actually do once it’s in you?
It latches onto IGF-1 receptors around the body and mimics the same growth signal natural IGF-1 sends, encouraging cell growth, protein building, and glucose uptake into muscle. The catch is those receptors aren’t only in muscle, they’re in organs, connective tissue, and potentially in tumor cells too, so the effect isn’t selective just because you want it to be. Solid human research here is scarce; most of what we have comes from animal studies or from clinical work in people with actual IGF-1 deficiency, not from healthy adults chasing bigger muscles.
What side effects do people actually report?
Low blood sugar is the fastest and scariest one, since the compound pushes glucose into cells and levels can drop quickly, especially around exercise. People also mention swelling in the jaw and hands, joint pain, and headaches that won’t quit. Longer term, there’s the cancer-risk question tied to IGF-1’s role in cell growth, though no controlled human trial has pinned down exact risk thresholds for people using it at bodybuilding-style amounts.
Is it legal to buy and use?
In the US, it isn’t approved for any use, so selling it as a supplement or drug isn’t legal, and most sellers operate in a regulatory gray zone or flatly break federal law. WADA bans it in sport. The one accountable, above-board path in the US is physician-supervised compounding, through a pharmacy like FormBlends, where sourcing and monitoring actually happen. Buying powder from a research-chemical website carries real legal risk on top of the safety risk.
References
- [C1] Mongongu C, Coudoré F, Domergue V, et al. Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes. Drug Testing and Analysis, 2021;13(7):1256-1269. States IGF-I and its analogs including LongR3 “were never approved for use in humans” yet “are readily available as black market products for bodybuilding,” and reports “abundant signs of lower quality, oxidized peptide forms” in black-market products. https://pubmed.ncbi.nlm.nih.gov/33587816/
- [C2] Kohler M, Thomas A, Walpurgis K, et al. Detection of His-tagged Long-R3-IGF-I in a black market product. Growth Hormone & IGF Research, 2010;20(5):386-390. A black-market injection vial was identified as His-tagged Long-R3-IGF-I, a form “usually produced for biochemical studies,” concluded to “may rather be a by-product from biochemical studies than synthesized for injection purposes.” https://pubmed.ncbi.nlm.nih.gov/20675162/
- [C3] Xi G, Kamanga-Sollo E, Pampusch MS, et al. Effect of recombinant porcine IGFBP-3 on IGF-I and long-R3-IGF-I-stimulated proliferation and differentiation of L6 myogenic cells. Journal of Cellular Physiology, 2004;200(3):387-394. Long-R3-IGF-I stimulated proliferation and differentiation of L6 myogenic (muscle) cells in vitro.
- [C6] Barton ER, Pham J, Brisson BK, et al. Functional muscle hypertrophy by increased insulin-like growth factor 1 does not require dysferlin. Muscle & Nerve, 2019;60(4):464-473. Increasing IGF-1 (native) expression in mouse muscle produced functional hypertrophy, stronger in males than females (animal study, native IGF-1, not LR3).
- [C7] Fang B, Xiao H, Fang Z. Serum insulin-like growth factor-1 and epidemiological evidence of the risk of prostate cancer. Frontiers in Oncology, 2026;15:1730382. Systematic review and meta-analysis of 16 studies: higher serum IGF-I associated with increased prostate-cancer risk (OR 1.10, 95% CI 1.02-1.18), dose-response relationship unclear.
- [C8] Kohler M, Thomas A, Geyer H, et al. Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the Cologne Doping Control Laboratory 2009. Drug Testing and Analysis, 2010;2(11-12):533-537. Lists “unpurified long-R(3)-IGF-1” among confiscated black-market products analyzed.
- [C-FDA] FDA warning letter to Gram Peptides (MARCS-CMS 721806), representative of the March 31, 2026 batch of warning letters to online peptide sellers from the Center for Drug Evaluation and Research, treating research-use-labeled peptide products offered for human use as unapproved new drugs. FDA, March 31, 2026.
- [C-WADA] World Anti-Doping Agency Prohibited List. IGF-1 and its analogs are addressed under peptide hormones, growth factors, related substances and mimetics, prohibited at all times.
Written by Ximena Quang, analytics writer. Last reviewed June 2026.
For background only. Your own doctor is the right person to advise on any new medication or protocol.
